BAIYUNSHAN PH Issues Supplemental Disclosure to 2025 Annual Report, Confirms Chapter 14A Compliance

Bulletin Express

2 hours ago

BAIYUNSHAN PH (Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited) released a supplemental announcement on 10 September 2026 addressing its Annual Report for the year ended 31 December 2025, originally published on 22 April 2026.

The company confirmed full compliance with Chapter 14A of the Hong Kong Stock Exchange Listing Rules concerning the disclosure and handling of related-party transactions. All information required under these regulations has been properly reported.

Management emphasized that the additional disclosure does not modify any other figures, statements, or analyses contained in the 2025 Annual Report; all previously published information remains unchanged.

The board currently comprises six executive directors (Chen Jiehui, Yuan Cheng, Cheng Hongjin, Tang Heping, Liu Lan, and Liu Hong), one non-executive director (Huang Jiyuan), and four independent non-executive directors (Wong Lung Tak Patrick, Sun Baoqing, Wu Xiangneng, and Yang Yinbao).

The announcement carries no other operational or financial revisions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/news/1124280699"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124280699\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124280699?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-10 17:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124280699","market":"hk","top_or_hot":-1,"title":"BAIYUNSHAN PH Issues Supplemental Disclosure to 2025 Annual Report, Confirms Chapter 14A Compliance","media":"Bulletin Express","content":"<p>BAIYUNSHAN PH (Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited) released a supplemental announcement on 10 September 2026 addressing its Annual Report for the year ended 31 December 2025, originally published on 22 April 2026.</p>\n<p>The company confirmed full compliance with Chapter 14A of the Hong Kong Stock Exchange Listing Rules concerning the disclosure and handling of related-party transactions. All information required under these regulations has been properly reported.</p>\n<p>Management emphasized that the additional disclosure does not modify any other figures, statements, or analyses contained in the 2025 Annual Report; all previously published information remains unchanged.</p>\n<p>The board currently comprises six executive directors (Chen Jiehui, Yuan Cheng, Cheng Hongjin, Tang Heping, Liu Lan, and Liu Hong), one non-executive director (Huang Jiyuan), and four independent non-executive directors (Wong Lung Tak Patrick, Sun Baoqing, Wu Xiangneng, and Yang Yinbao).</p>\n<p>The announcement carries no other operational or financial revisions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAIYUNSHAN PH Issues Supplemental Disclosure to 2025 Annual Report, Confirms Chapter 14A Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAIYUNSHAN PH Issues Supplemental Disclosure to 2025 Annual Report, Confirms Chapter 14A Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-10 17:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAIYUNSHAN PH (Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited) released a supplemental announcement on 10 September 2026 addressing its Annual Report for the year ended 31 December 2025, originally published on 22 April 2026.</p>\n<p>The company confirmed full compliance with Chapter 14A of the Hong Kong Stock Exchange Listing Rules concerning the disclosure and handling of related-party transactions. All information required under these regulations has been properly reported.</p>\n<p>Management emphasized that the additional disclosure does not modify any other figures, statements, or analyses contained in the 2025 Annual Report; all previously published information remains unchanged.</p>\n<p>The board currently comprises six executive directors (Chen Jiehui, Yuan Cheng, Cheng Hongjin, Tang Heping, Liu Lan, and Liu Hong), one non-executive director (Huang Jiyuan), and four independent non-executive directors (Wong Lung Tak Patrick, Sun Baoqing, Wu Xiangneng, and Yang Yinbao).</p>\n<p>The announcement carries no other operational or financial revisions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00874","symbol_name":"白云山","start_time":0,"source_url":"","article_id":"1124280699","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124280699","pubTimestamp":1789033285,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"BAIYUNSHAN PH (Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited) released a supplemental announcement on 10 September 2026 addressing its Annual Report for the year ended 31 December...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00874":"白云山"},"translate_title":"白云山PH发布2025年年报补充披露，确认符合第14A章规定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00874":1},"content_text":"BAIYUNSHAN PH (Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited) released a supplemental announcement on 10 September 2026 addressing its Annual Report for the year ended 31 December 2025, originally published on 22 April 2026.\nThe company confirmed full compliance with Chapter 14A of the Hong Kong Stock Exchange Listing Rules concerning the disclosure and handling of related-party transactions. All information required under these regulations has been properly reported.\nManagement emphasized that the additional disclosure does not modify any other figures, statements, or analyses contained in the 2025 Annual Report; all previously published information remains unchanged.\nThe board currently comprises six executive directors (Chen Jiehui, Yuan Cheng, Cheng Hongjin, Tang Heping, Liu Lan, and Liu Hong), one non-executive director (Huang Jiyuan), and four independent non-executive directors (Wong Lung Tak Patrick, Sun Baoqing, Wu Xiangneng, and Yang Yinbao).\nThe announcement carries no other operational or financial revisions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}